June 22, 2016 10:38 AM EDT
People
R&D

Gary Glick gets $27M to leap back in­to im­muno-on­col­o­gy R&D with No­var­tis, At­las and Abing­worth in his cor­ner

John Carroll

Editor & Founder

 

Gary Glick didn’t specif­i­cal­ly in­tend to start a new biotech af­ter he left Lyc­era, where he was the founder and CSO, a lit­tle more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times